ArticlePakistan journal of medical sciences2026
Anti-nuclear antibodies in patients with suspicion of neuromyelitis optica spectrum disorder: Frequency and significance.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgroud & Objectives: Neuromyelitis Optica spectrum disorder (NMOSD) is an autoimmune inflammatory disease involving optic nerves and spinal cord. The association of NMOSD with anti-nuclear antibodies and autoimmune disorders has been reported. This study was conducted to determine frequency of anti-nuclear antibodies (ANA) in patients with NMOSD and to observe for the development of symptoms related to autoimmune disorders on follow up. Methodology: After approval from Institutional Review Board, this cross-sectional study was conducted at Immunology Department, Shifa International Hospital, Islamabad, Pakistan and after informed verbal consent from patients, serum samples were tested by indirect immunofluorescence for anti-aquaporin four antibodies (AQP-4) and ANA. Clinical data of patient was collected via a structured questionnaire. Follow-up of 6-12 months was conducted in patients who were positive for ANA. Results: Total 248 patients were included in this study of which 32 were positive for AQP4- Antibodies (mean age 32.4 ± 14.1 years), out of which ANA was positive in 17 (53%) patients whereas in AQP-4 negative group, ANA was positive in 70 (32%) patients. At one year follow-up, in AQP-4 and ANA positive group, two patients were diagnosed with autoimmune thyroid disorders and one patient was diagnosed with Systemic Lupus Erythematosus. Conclusion: In this study, we concluded that ANA were observed more frequently with AQP-4 antibody positivity. Considering this, detection of ANA in AQP-4 antibody positive patients may help in establishing early diagnosis of an accompanying autoimmune disease leading to early diagnosis and an overall favorable outcome in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.